Rasio rega marang prakiraan pendapatan neurocrine.com (NBIX)

Lambang korporat lan logo Neurocrine Corp (NBIX)

The fundamental success of Neurocrine Biosciences (NBIX) relies on Ingrezza's dominance in dyskinesia therapy and FDA approval of new molecules. The forward price-to-sales ratio clearly demonstrates market expectations, with the indicator standing at 3.30. A steady influx of patients is ensured by the absence of analogues, while innovation is accelerated through strategic partnerships with global pharma behemoths and joint research.

Neurocrine - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NBIX (periode 04.07.2022 - 18.11.2026)

Neurocrine Biosciences (NBIX) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:
Analisis komprehensif perusahaan:NBIX (neurocrine.com)
Sampel barang Neurocrine Corp

The forward P/S ratio determines the market value of a company relative to its expected sales volume, making it possible to identify whether an asset is overvalued or hiddenly undervalued. Investors utilize this multiple to distinguish fundamentally strong companies from "value traps," where a low ratio signals business degradation. When analyzing the forward price-to-sales chart for Neurocrine Biosciences (NBIX), it is critical to consider the revenue dependence on the patent protection of a narrow drug portfolio and the risks associated with clinical trials.

Analisis pesaing

Multiplikator Forward P/S BIIB (Biogen Idec)|Regencell Bioscience - Rasio rega marang prakiraan pendapatan|Axsome Therapeutics - Multiplikator Forward P/S|Rega forward marang dodolan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator Forward P/S|CPRX: Rega forward marang dodolan|Multiplikator Forward P/S DNLI|Rasio kapitalisasi marang dodolan sing dikarepake Harmony Biosciences|Biohaven Ltd - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Praxis Corp PRAX|AVXL: Multiplikator Forward P/S|CBLL (ceribell.com) - Rasio rega marang prakiraan pendapatan|PRTA (Prothena Corporation) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan alector.com (ALEC)|Rasio rega marang prakiraan pendapatan Annexon, Inc. (ANNX)|OMER - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Voyager Therapeutics Inc - Multiplikator Forward P/S|Neumora (NMRA) - Multiplikator forward rega marang pendapatan|SCLX: Multiplikator Forward P/S|TVGN - Rasio kapitalisasi marang dodolan sing dikarepake|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cogrx.com (CGTX)|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics Inc (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake Cassava Sciences|Multiplikator Forward P/S ASRT (Assertio Holdings)|COYA - Multiplikator forward rega marang pendapatan|vistagen.com - Multiplikator Forward P/S|OVID: Rasio rega marang prakiraan pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang prakiraan pendapatan|CervoMed Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S